Bibliography
- Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12:175-80
- Larsen JE, Cascone T, Gerber DE, Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 2011;17:512-27
- McDermott U, Settleman J. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 2009;27:5650-9
- Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer–is it becoming a reality? Nat Rev Clin Oncol 2010;7:401-14
- Chiarle R, Voena C, Ambrogio C, The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23
- Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703
- Butrynski JE, D'Adamo DR, Hornick JL, Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33
- Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011;364:775-6
- Shaw AT, Yeap BY, Solomon B, Effect of crizotinib on overall survival in patients with advanced nonsmall-cell lung cancer harbouringALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;11:1004-12
- Choi YL, Soda M, Yamashita Y, EML4-ALK mutations in Lung Cancer that confer resistance to ALK inhbitors. N Engl J Med 2010;363:1734-9
- Katayama R, Shaw AT, Khan TM, Mechanisms of acquired Crizotinib resistance in ALK-rearranged lung cancer. Sci Transl Med 2012;4:120ra117
- Katayama R, Khan TM, Benes C, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci 2011;108:7535-40
- Sasaki T, Koivunen J, Ogino A, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011;71:6051-60
- Sakamoto H, Tsukaguchi T, Hiroshima S, CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90
- Bresler SC, Wood AC, Haglund EA, Differential inhibitor sensitivity of Anaplastic Lymphoma Kinase variants found in neuroblastoma. Sci Transl Med 2011;3:108ra114
- Sasaki T, Okuda W, Zheng J, The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 2010;70:10038-43
- Doebele RC, Pilling AB, Aisner DL, Mechanisms of resistance to Crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82
- Doebele RC, Aisner DL, Le AT, Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. J Clin Oncol 2012. (Suppl 30):a7504
- Chen Z, Sasaki T, Tan X, Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 2010;70:9827-36
- Normant E, Paez G, West KA, The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. Oncogene 2011;30:2581-6
- Sequist LV, Gettinger S, Senzer NN, Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60